PeptidePedia The community reference

Contributions of OrforglipronOona

User contributions·24 logged edits·page 1 of 1

Contributions by OrforglipronOona, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 4,103 edits includes activity predating the current log.

  1. 20:10, 16 Jul 2026 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 add the structural figure and caption it properly
  2. 12:33, 10 Jun 2026 (diff | hist) Triple agonist 4,269 ±0 expand §Why three receptors
  3. 03:06, 13 May 2026 (diff | hist) Cagrilintide 4,256 ±0 fix the amino-acid substitution — position 8, not position 2
  4. 09:20, 3 May 2026 (diff | hist) Talk:Orforglipron 822 +98 /* Cross-trial comparison in the last section */ reply
  5. 10:10, 2 May 2026 (diff | hist) Talk:Orforglipron 400 +151 /* Cross-trial comparison in the last section */ new section
  6. 04:37, 23 Mar 2026 (diff | hist) Exenatide 5,754 ±0 add CAS number, sourced
  7. 04:14, 26 Jan 2026 (diff | hist) Tirzepatide 8,037 ±0 unpipe a link that did not need piping
  8. 02:36, 5 Jan 2026 (diff | hist) Bacterial endotoxin test 5,317 ±0 correct the integration description — valley-to-valley, not drop-line
  9. 19:33, 31 Dec 2025 (diff | hist) Number needed to treat 4,718 ±0 m correct the endpoint hierarchy — that was a secondary endpoint
  10. 03:38, 9 Dec 2025 (diff | hist) GLP-1 receptor agonist 11,264 ±0 ce
  11. 00:27, 15 Oct 2025 (diff | hist) USP General Chapter 71 4,657 ±0 clarify that area percent is not mass percent
  12. 02:51, 6 Oct 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 8,265 ±0 ce
  13. 22:37, 21 Aug 2025 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 fix a broken wikilink
  14. 01:20, 16 Aug 2025 (diff | hist) Liraglutide 5,967 ±0 rm the comparison to a compound with no published head-to-head data
  15. 03:51, 31 Jul 2025 (diff | hist) CagriSema 5,302 ±0 move the trade-name history out of the lead and into §Regulatory history
  16. 12:43, 25 Jun 2025 (diff | hist) Counterfeit peptide 4,235 ±0 add the second-opinion point: two services, one lot, is a stronger record
  17. 03:47, 15 May 2025 (diff | hist) Third-party testing 6,906 +1,136 clarify that agreement between certificate and report is a weak finding
  18. 15:34, 12 Apr 2025 (diff | hist) Exenatide 4,449 +161 expand §The extended-release formulation
  19. 12:46, 29 Jan 2025 (diff | hist) Dual incretin agonist 4,587 ±0 state plainly that the research-use-only form is not approved for human use
  20. 00:16, 6 Jan 2025 (diff | hist) Glucagon 4,913 +26 m add the excipient list from the labelling
  21. 02:11, 3 Jan 2025 (diff | hist) CagriSema 2,915 ±0 m state plainly that the research-use-only form is not approved for human use
  22. 06:29, 6 Dec 2024 (diff | hist) Tirzepatide 5,345 +225 de-duplicate a repeated sentence
  23. 10:04, 30 Oct 2024 (diff | hist) Semaglutide 5,608 +30 convert the substitution list to a table so the analogues line up
  24. 02:38, 29 Sep 2024 (diff | hist) Semaglutide 5,011 ±0 m add the year of first marketing authorisation, with the regulator named